Get the Stockscreener App
273.41
0.19%
0.53
After Hours:
273.41
Charles River Laboratories International Inc stock is traded at $273.41, with a volume of 1.01M.
It is up +0.19% in the last 24 hours and down -2.37% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$272.88
Open:
$272.78
24h Volume:
1.01M
Relative Volume:
1.15
Market Cap:
$13.05B
Revenue:
$4.03B
Net Income/Loss:
$-182.84M
P/E Ratio:
-72.71
EPS:
-3.7603
Net Cash Flow:
$391.29M
1W Performance:
-1.77%
1M Performance:
-2.37%
6M Performance:
+79.91%
1Y Performance:
+80.35%
1-Day Range:
$270.88
$282.90
1-Week Range:
$267.27
$282.90
52-Week Range:
$144.26
$303.31
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
273.41 | 13.28B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
648.43 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
208.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
345.34 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
268.82 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.69 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-29-26 | Upgrade | CLSA | Hold → Outperform |
| Apr-14-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-17-25 | Upgrade | Argus | Hold → Buy |
| Nov-06-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Should Automated Test Cartridge Expansion Require Action From Charles River Shares Investors? - simplywall.st
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Labs stock edges lower as investors weigh FY 2026 guidance and conference schedule - ad-hoc-news.de
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences - Yahoo! Finance Canada
Charles River Labs stock heads into the open after a 1.4% dip - ad-hoc-news.de
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Charles River Labs stock trades near TD Cowen target as Amundi trims position - ad-hoc-news.de
Charles River Labs stock heads into the open after a 0.3 percent dip - ad-hoc-news.de
Charles River Labs stock trades near TD Cowen target after recent gains - ad-hoc-news.de
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Laboratories International (CRL) Could Be 8% Undervalued After Endosafe Automation Ramp - simplywall.st
One investor controls millions of Charles River (NYSE: CRL) shares - Stock Titan
Charles River Launches Automated Endosafe Manufacturing Suite - Contract Pharma
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite - Investing News Network
Charles River now inspects every testing cartridge, not just samples - Stock Titan
Charles River Laboratories Inte (CRL): Analyst Consensus and Growth Potential Amidst Market Volatility - DirectorsTalk Interviews
Charles River Labs stock holds steady as investors look to recent earnings - ad-hoc-news.de
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Charles River Labs stock trades near yearly high as analysts flag valuation risks - ad-hoc-news.de
Charles River Laboratories stock gains as valuation stretches above fair value estimates - ad-hoc-news.de
How Investors Are Reacting To Charles River (CRL) Deepening Its Role In Complex Vaccine Development - simplywall.st
Charles River Laboratories International Inc (CRL) Shares Surge 3.3% -- What GF Score of 70 Tells Investors - GuruFocus
LRT Capital Management, LLC's Charles River Laboratories International Inc(CRL) Holding History - GuruFocus
Is This the Right Time to Add CRL Stock to Your Portfolio? - TradingView
Charles River Labs stock holds near recent highs as earnings beat and analyst optimism support the r - ad-hoc-news.de
Is Charles River Laboratories International (CRL) Cheap After Its Medigen Vaccine Partnership? - simplywall.st
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River Laboratories (CRL) Stock Analysis: Navigating Growth Challenges with Strategic Collaborations - DirectorsTalk Interviews
Charles River Laboratories (CRL) Earnings History & Trends - 24/7 Wall St.
Resilient Charles River Labs stock trades close to its 52-week high as analysts see limited upside - AD HOC NEWS
Charles River (NYSE: CRL) director exercises options, sells stock at $300 - Stock Titan
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock? - Yahoo Finance
Charles River (NYSE: CRL) director plans new sale after $24.8M stock sales - Stock Titan
Charles River and Medigen partner to speed up next-generation Enterovirus vaccine - Indian Pharma Post
Is Charles River (CRL) Quietly Redefining Its Edge Through Complex Biologics and Vaccine Testing? - simplywall.st
Charles River Labs stock holds close to new 52-week high as Q2 2026 beat and guidance hike support r - ad-hoc-news.de
Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge? - Yahoo Finance
What Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration? - simplywall.st
Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development? - Yahoo Finance
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running? - TradingView
Charles River Labs stock holds near fresh 52-week high after strong Q2 earnings - ad-hoc-news.de
Are Options Traders Betting on a Big Move in Charles River Stock? - TradingView
Charles River Gains 88.6% in a Year: What's Driving the Rally? - Yahoo Finance
Madison Asset Management LLC Invests $3.81 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs CEO Birgit Girshick Gifts 528 Shares, Retains Significant Ownership - Kalkine Media
Charles River Laboratories Director Nancy C. Andrews Reports Form 4 Filing on Stock Option Exercise and Sale - Kalkine Media
Charles River Labs CEVP Parisotto sells $599,710 in shares By Investing.com - Investing.com Australia
Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares - MarketBeat
Charles River (NYSE: CRL) CEO makes 528-share gift of common stock - Stock Titan
Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):